Pelthos Therapeutics Inc. (PTHS)

Market Cap	75.90M
Revenue (ttm)	7.41M
Net Income	-23.58M
EPS	-19.07
Shares Out	3.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,524
Open	25.45
Previous Close	24.69
Day's Range	24.77 - 25.45
52-Week Range	9.00 - 54.29
Beta	n/a
Analysts	Strong Buy
Price Target	56.75 (+130.79%)
Earnings Date	Mar 27, 2026

About PTHS

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durh...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 11
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTHS
• Website: https://pelthos.com

Analyst Summary

According to 4 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $56.75, which is an increase of 130.79% from the latest price.

Price Target

$56.75

(130.79% upside)

Analyst Consensus: Strong Buy